Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
AstraZeneca
Baxter
Johnson and Johnson
Dow
UBS
Merck
Boehringer Ingelheim
Harvard Business School

Generated: October 23, 2017

DrugPatentWatch Database Preview

Abbvie Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ABBVIE INC, and what generic alternatives to ABBVIE INC drugs are available?

ABBVIE INC has eight approved drugs.

There are thirty-five US patents protecting ABBVIE INC drugs.

There are seven hundred patent family members on ABBVIE INC drugs in sixty-three countries and forty-six supplementary protection certificates in thirteen countries.

Summary for Applicant: Abbvie Inc

International Patents:700
US Patents:35
Tradenames:8
Ingredients:8
NDAs:8
Drug Master File Entries: (click here to view)17
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc
VIEKIRA XR
dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
TABLET, EXTENDED RELEASE;ORAL208624-001Jul 22, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Abbvie Inc
TRICOR
fenofibrate
TABLET;ORAL021203-003Sep 4, 2001DISCNYesNo► Subscribe► Subscribe ► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-003Apr 11, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Abbvie Inc
TRICOR
fenofibrate
TABLET;ORAL021203-001Sep 4, 2001DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Abbvie Inc
DUOPA
carbidopa; levodopa
SUSPENSION;ENTERAL203952-001Jan 9, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-001Apr 11, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Abbvie Inc
DUOPA
carbidopa; levodopa
SUSPENSION;ENTERAL203952-001Jan 9, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Abbvie Inc
VIEKIRA XR
dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
TABLET, EXTENDED RELEASE;ORAL208624-001Jul 22, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Abbvie Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Inc
TRICOR
fenofibrate
TABLET;ORAL021203-001Sep 4, 2001► Subscribe► Subscribe
Abbvie Inc
TECHNIVIE
ombitasvir; paritaprevir; ritonavir
TABLET;ORAL207931-001Jul 24, 2015► Subscribe► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014► Subscribe► Subscribe
Abbvie Inc
TRICOR
fenofibrate
TABLET;ORAL021203-003Sep 4, 2001► Subscribe► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014► Subscribe► Subscribe
Abbvie Inc
TECHNIVIE
ombitasvir; paritaprevir; ritonavir
TABLET;ORAL207931-001Jul 24, 2015► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ABBVIE INC drugs

Drugname Dosage Strength Tradename Submissiondate
ritonavir
Capsules100 mg
NORVIR
10/31/2012
ritonavir
Tablets100 mg
NORVIR
12/21/2010
fenofibrate
Tablets48 mg
TRICOR
7/1/2008
fenofibrate
Tablets145 mg
TRICOR
10/19/2007

Non-Orange Book Patents for Abbvie Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,183,416Polymorph of a pharmaceutical► Subscribe
8,332,661Method and apparatus for prevention of tampering, unauthorized use, and unauthorized extraction of information from microdevices► Subscribe
8,309,613Solid pharmaceutical dosage form► Subscribe
6,596,317 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it► Subscribe
8,377,952Solid pharmaceutical dosage formulation► Subscribe
9,586,978Anti-viral compounds► Subscribe
8,025,899Solid pharmaceutical dosage form► Subscribe
9,023,8782-iminobiotin formulations and uses thereof► Subscribe
8,937,150Anti-viral compounds► Subscribe
8,691,878Solid pharmaceutical dosage form► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Abbvie Inc Drugs

Country Document Number Estimated Expiration
Norway2015011► Subscribe
Denmark2576546► Subscribe
Ukraine61096► Subscribe
Taiwan201247648► Subscribe
Malaysia155645► Subscribe
Hong Kong1053783► Subscribe
World Intellectual Property Organization (WIPO)2011156578► Subscribe
New Zealand604498► Subscribe
Canada2851104► Subscribe
Austria514002► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Abbvie Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2203431/01Switzerland► SubscribeBEI DER ANMELDUNG WURDE DER INHABER IRRTUEMLICH DOPPELT ERFASST.
668Luxembourg► SubscribePRODUCT NAME: OMBITASVIR, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE (VIEKIRAX R); FIRST REGISTRATION DATE: 20150119
/2015Austria► SubscribePRODUCT NAME: DASABUVIR ODER EIN SALZ DAVON, EINSCHLIESSLICH DASABUVIR-NATRIUM-MONOHYDRAT; REGISTRATION NO/DATE: EU/1/14/983 20150115
0150015 00143Estonia► SubscribePRODUCT NAME: DASABUVIIR;REG NO/DATE: EU/1/14/983 19.01.2015
C/GB01/044United Kingdom► SubscribePRODUCT NAME: THE COMBINATION OF THE ACTIVE INGREDIENTS RITONAVIR AND LOPINAVIR; REGISTERED: CH 55649 20001213; UK EU/1/01/172/001 20010320; UK EU/1/01/172/002 20010320; UK EU/1/01/172/003 20010320
2015012,C2368890Lithuania► SubscribePRODUCT NAME: OMBITASVIRAS; REGISTRATION NO/DATE: EU/1/14/982 20150115
2015013,C2203431Lithuania► SubscribePRODUCT NAME: DASABUVIRAS; REGISTRATION NO/DATE: EU/1/14/983 20150115
2340029/01Switzerland► SubscribePRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: SWISSMEDIC 65301 25.11.2014
C0021France► SubscribePRODUCT NAME: PARITAPREVIR DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/14/982 20150119
2017 00021Denmark► SubscribePRODUCT NAME: VENETOCLAX; REG. NO/DATE: EU/1/16/1138/001-007 20161207
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Covington
Healthtrust
Johnson and Johnson
Cipla
Julphar
Citi
US Department of Justice
Argus Health
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot